



EVITRADE Health Systems Corporation

EVITRADE Health Announces Cancellation of \$1MM Financing at \$2.50 and Cancellation of 75,000 Options for Directors and Consultants

VANCOUVER, BC, Friday November 25, 2016 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF) (the “Company” or “EVITRADE”) announces that it has cancelled the current non-brokered private placement financing priced at \$2.50 for up to \$1 million. The company is evaluation the two recent MOUs signed and is expected to announce a new private placement after completing its due diligence on the possible transactions. The current funds of over \$500,000 that had been booked for the financing will remain as debt on the Company’s books with no interest and no terms of repayment.

In addition, the Company has cancelled 75,000 options to three directors and two consultants under section 12 of the Company’s Option Agreements with the parties. As a result all remaining options outstanding in the Company are now priced at either \$2.25 or \$3.00.

Contact:

Syd Au, Chairman and CEO

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email: ceo@auxellence.com

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLD)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

About C&C Cosmeceuticals Corp. (wholly owned subsidiary of the Company)

C&C Cosmeceuticals Corp. was founded in 2011 to develop, manufacture and market nutraceutical and cosmeceutical personal healthcare products and services. It was the predecessor company that acquired Auxellence Health Corporation, which is now named EVITRADE Health Systems Corp. and is currently a wholly owned subsidiary. As per the September 2, 2016 press release from the parent company, and the



**EViTRADE
Health
Systems
Corporation**

EViTRADE Health Systems Corporation

follow up November 9, 2016 press release from the parent company, C&C is likely to be voted upon to be dividdened or divested from the company and all shareholders on record as of November 15, 2016 will be entitled to vote on that motion, at the Annual General and Special Meeting and any shareholders that are officially holders of record as of December 15, 2016 in the parent company are expected to receive a pro-rata distribution of the shares in the subsidiary in the event the motion is successfully passed.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.